{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"294"},{"groupId":"OG001","value":"144"}],"units":"Participants"}],"description":"Clinical response defined by decrease in modified Mayo score from baseline of at least 2 points and at least 30%, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1 point. Patients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 were considered as non-responder.","groups":[{"description":"CT-P13 SC 120 mg","id":"OG000","title":"CT-P13 SC 120 mg"},{"description":"Placebo","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All-randomized population","reportingStatus":"POSTED","timeFrame":"Week 54","title":"Percentage Patients Achieving Clinical Response at Week 54","type":"SECONDARY","unitOfMeasure":"Participants"}